ライフサイエンスコーパス: antitumor efficacy

1 ity, which has been associated with superior antitumor efficacy.

2 phery to mild hyperthermia and increases RFA antitumor efficacy.

3 een by alpha-GalCer that might attenuate its antitumor efficacy.

4 channel-modulating agents have demonstrated antitumor efficacy.

5 5TNFR mitigates TNF toxicity without loss of antitumor efficacy.

6 lockade synergized with vaccine in eliciting antitumor efficacy.

7 e CD27 (mCD27) with agonist mAbs can mediate antitumor efficacy.

8 and adaptive immunity will result in better antitumor efficacy.

9 of transferred T cells can lead to improved antitumor efficacy.

10 ic T cells, with trafficking correlated with antitumor efficacy.

11 its poor bioavailability in vivo limits its antitumor efficacy.

12 IDO targeting for ethyl pyruvate to achieve antitumor efficacy.

13 immunization strategies to achieve enhanced antitumor efficacy.

14 ivalent to those associated with preclinical antitumor efficacy.

15 ncer, beta-lap synergized with IR to promote antitumor efficacy.

16 n-7 receptor, heightened apoptosis, and poor antitumor efficacy.

17 ed enhancement of CD8+ T-cell activation and antitumor efficacy.

18 repeats), has significant antiangiogenic and antitumor efficacy.

19 irect intracerebral inoculation in mice, and antitumor efficacy.

20 s that target multiple pathways for enhanced antitumor efficacy.

21 of CD25(hi) T cells did not further improve antitumor efficacy.

22 tments, limiting tolerance opposing systemic antitumor efficacy.

23 or-specific CD8 T-cell activity and improved antitumor efficacy.

24 y using this approach, without compromise to antitumor efficacy.

25 intratumoral virus delivery/penetration and antitumor efficacy.

26 zing transgene would increase virus-mediated antitumor efficacy.

27 t of these receptors is critical for optimal antitumor efficacy.

28 n effective approach to assess potential for antitumor efficacy.

29 ant effect of preexisting immunity on vector antitumor efficacy.

30 increased ER stress and would enhance their antitumor efficacy.

31 lue of (89)Zr-bevacizumab PET for everolimus antitumor efficacy.

32 9 tumors in BALB/c mice, EC131 showed marked antitumor efficacy.

33 ombination with chemotherapy, would increase antitumor efficacy.

34 F, and IFN-gamma were essential for complete antitumor efficacy.

35 d intratumoral delivery of CTLs and improved antitumor efficacy.

36 )-derived T cells, their function, and their antitumor efficacy.

37 d to characterize their in vitro and in vivo antitumor efficacy.

38 with immune therapy may result in increased antitumor efficacy.

39 munostimulatory molecules have shown limited antitumor efficacy.

40 cells with a costimulator can enhance their antitumor efficacy.

41 duced neutropenia and anemia while retaining antitumor efficacy.

42 the tumor microenvironment, eliciting potent antitumor efficacy.

43 uppressive immune-modulating agents (IMs) on antitumor efficacy.

44 CTL combined with CTLA4 blockade might boost antitumor efficacy.

45 cargoes in tumor cells, leading to enhanced antitumor efficacy.

46 ting that sequential schedules could improve antitumor efficacy.

47 elf-tumor antigen positively correlated with antitumor efficacy.

48 rapalogs-mediated immune modulation on their antitumor efficacy.

49 rapy of lung cancer with improved safety and antitumor efficacy.

50 therapy and chemotherapy to receive superior antitumor efficacy.

51 early exhaustion of CAR T cells that limits antitumor efficacy.

52 al small-molecular drug, leading to enhanced antitumor efficacy.

53 mcitabine as an optimal protocol to maximize antitumor efficacy.

54 fic chemosensitivity patterns and to monitor antitumor efficacy.

55 tor T-cell responses, to augment therapeutic antitumor efficacy (66% reduction in tumor growth; P = .

56 od mononuclear cells or T cells enhanced the antitumor efficacy achieved by the parental counterpart.

57 ped a mouse CD19-specific CAR to investigate antitumor efficacy against a syngeneic B cell lymphoma c

58 icular, compound 48 demonstrated significant antitumor efficacy against established HT29 human colon

59 standard chemotherapy drug for GBM increased antitumor efficacy against glioblastoma in experimental

60 ilencing with RIG-I signaling confers potent antitumor efficacy against pancreatic cancer by breaking

61 rophic for leu-arg, is tumor-seeking and has antitumor efficacy against the major types of cancer.

62 combined with radiation, ABDNAZ accentuated antitumor efficacy along with the therapeutic index.

63 Antitumor efficacy analyses in mice bearing subcutaneous

64 ases, as well as pan-Aurora inhibitors, show antitumor efficacy and are now under clinical investigat

65 reprogramming of T cells to achieve superior antitumor efficacy and even complete cures.

66 geneic mouse tumor models, 1F5 showed potent antitumor efficacy and induction of protective immunity,

67 Similar in vivo antitumor efficacy and intratumoral CD8(+)/regulatory T

68 ocal heat that has already shown substantial antitumor efficacy and is in human trials.

69 tly into tumor cells with consequent greater antitumor efficacy and less systemic toxicity.

70 xel (PTX)-loaded OA02-NPs exhibited superior antitumor efficacy and lower systemic toxicity profile i

71 characterize a human IL-2 mutant with higher antitumor efficacy and lower toxicity than wild type hum

72 ta demonstrate that XmAbCD40 displays potent antitumor efficacy and merits further evaluation for the

73 he disease course, with a view to maximizing antitumor efficacy and minimizing overlapping toxicities

74 (DOX)-loaded SNP (SNP/DOX) shows significant antitumor efficacy and nearly eradicates the tumor, subs

75 oughout tumors correlated well with improved antitumor efficacy and overall survival in two highly me

76 nanochemistry for targeting PI3K to enhance antitumor efficacy and potentially overcome these limita

77 Synergistic antitumor efficacy and prolonged survival were noted in

78 Antitumor efficacy and regressions were observed in mult

79 tides in combination with docetaxel improved antitumor efficacy and resulted in lower expression leve

80 odel overexpressing GLUT1, compound 2 showed antitumor efficacy and selective uptake in tumors with n

81 combination is expected to have synergistic antitumor efficacy and significant potential for the tre

82 These effects were associated with increased antitumor efficacy and survival as compared with PI103 a

83 ave yielded promising, yet limited, signs of antitumor efficacy and therefore need to be improved for

84 Antitumor efficacy and toxicity were examined through a

85 ng nelfinavir might experience both enhanced antitumor efficacy and unexpected adverse toxicity given

86 mitigated antigen escape, displayed enhanced antitumor efficacy, and improved animal survival.

87 onucleotides with low doses of docetaxel has antitumor efficacy, and it may be an effective treatment

88 To improve its antitumor efficacy, and offer strategies for its combina

89 SERD), exhibiting good oral bioavailability, antitumor efficacy, and SERD activity in vivo.

90 Despite clear antitumor efficacy, antiangiogenic therapy did not alter

91 ct displayed comparable in vitro and in vivo antitumor efficacy as bivalent Herceptin/rGel conjugate.

92 is safe and well tolerated with evidence of antitumor efficacy assessed radiologically and serologic

93 unization with DNA and Ad5 produced superior antitumor efficacy associated with increased TCR avidity

94 tigen, gp100(pmel17/silver locus), improving antitumor efficacy, augmenting systemic CD8+ T-cell resp

95 Balancing antitumor efficacy, autoimmunity, and reconstitution of

96 their intratumoral proliferation and direct antitumor efficacy but did not block their capacity to s

97 ation from 30 to 60 mg/kg sorafenib improved antitumor efficacy but worsened survival due to excessiv

98 The established role of CD8(+) T cells in antitumor efficacy, but CD4(+) T cells in autoimmunity,

99 idity TCRs can be improved to increase their antitumor efficacy, but conventional saturation mutagene

100 gens in solid malignancies where it exhibits antitumor efficacy, but its clinical utility for treatin

101 yde interacts with anthracyclines to enhance antitumor efficacy, bypass resistance mechanisms, improv

102 espite having a shorter serum half-life, had antitumor efficacy comparable with equimolar v-mab; 22-2

103 F-5412 with sunitinib significantly improved antitumor efficacy compared with either agent alone.

104 ing A12 and radiation significantly enhances antitumor efficacy compared with either modality alone.

105 o, we show enhanced expansion and CAR T cell antitumor efficacy, culminating in improvement in surviv

106 quely safe profile of induced cytokines, and antitumor efficacy demonstrated in a number of animal mo

107 was cardioprotective and did not compromise antitumor efficacy, did not increase the frequencies of

108 Unexpectedly, despite the improved antitumor efficacy engendered by TMZ-induced lymphopenia

109 preexisting immunity in oncolytic Ad vector antitumor efficacy following intratumoral injection of v

110 ing immunity to Ad5 does not affect INGN 007 antitumor efficacy following intratumoral injection, but

111 We demonstrate superior antitumor efficacy for IgE compared with an otherwise id

112 These results establish proof-of-concept antitumor efficacy for tankyrase inhibitors in APC-mutan

113 In vivo antitumor efficacy for the anti-HER2 ADCs in Founder 5 w

114 with enhanced safety, pharmacokinetics, and antitumor efficacy for the specific treatment of NSCLC t

115 strategies attempts to decouple the observed antitumor efficacy from the on-target liver toxicity.

116 Striking antitumor efficacy has been achieved in preclinical canc

117 in well-characterized mouse models in which antitumor efficacy has been shown; inhibiting only late

118 erm PDK1 knockdown revealed a lack of potent antitumor efficacy in 3 different mouse models of PTEN-d

119 rgeting these nodes concurrently resulted in antitumor efficacy in a majority of cetuximab-resistant

120 N inhibits glutamine metabolism and provides antitumor efficacy in a murine model of glioblastoma, al

121 mice and demonstrated superior single-agent antitumor efficacy in a PPC-1 mouse xenograft model.

122 d show that the nanoparticle yields improved antitumor efficacy in a preclinical human melanoma xenog

123 and also demonstrated superior single-agent antitumor efficacy in a prostate cancer mouse xenograft

124 A-BN-PRO and resulted in a trend of improved antitumor efficacy in a PSA-expressing tumor model.

125 fortunately, intravesical IL-12 did not show antitumor efficacy in a recent clinical study of patient

126 Further, BH3 peptides demonstrate antitumor efficacy in a xenograft model of NB in the abs

127 NC280, a cMET inhibitor, resulted in durable antitumor efficacy in a xenograft model that initially d

128 nd an orally bioavailable compound (32) with antitumor efficacy in ALK-driven xenografts in mouse mod

129 y, sustained multi-drug exposure, and potent antitumor efficacy in an ES-2-luc, ovarian cancer i.p. x

130 endent gene expression in vivo, demonstrates antitumor efficacy in an MV-4-11 mouse xenograft model,

131 to Sutent (ED50 = 9 mg/kg) and showed potent antitumor efficacy in an MX-1 human breast carcinoma xen

132 Furthermore, dinaciclib revealed in vivo antitumor efficacy in an orthotopic xenograft mouse mode

133 xcellent activity in vitro and in vivo, with antitumor efficacy in both subcutaneous and orthotopic x

134 is-platinum nanoparticle results in enhanced antitumor efficacy in breast cancer as compared with whe

135 may lead to enhanced and sustained clinical antitumor efficacy in CRCs harboring the BRAF(V600E) mut

136 lly, the CH-NPs showed significantly greater antitumor efficacy in EG.7 and TC-1 tumor-bearing mice c

137 revents the PIP3 rebound and induces greater antitumor efficacy in HER2-amplified and PIK3CA mutant c

138 tudies revealed that FL118 exhibits superior antitumor efficacy in human tumor xenograft models in co

139 IFNgamma was implicated, given a lack of antitumor efficacy in IFNgamma(-/-) mice.

140 characteristics of the drug, with equivalent antitumor efficacy in LNCaP xenografts at 1/3 the dose o

141 BRAF inhibitors have demonstrated antitumor efficacy in melanoma therapy but have also bee

142 eover, in vivo peptide administration showed antitumor efficacy in mice bearing Hepa129 or TC1 tumor

143 This prodrug leads to superior antitumor efficacy in mice compared to HMR 1826, a well-

144 eting the constant region of CD44 that shows antitumor efficacy in mice implanted with CD44-expressin

145 ion of these compounds would yield increased antitumor efficacy in multiple myeloma and glioblastoma

146 icles exhibit significantly enhanced in vivo antitumor efficacy in murine 4T1 breast cancer and in K-

147 , navitoclax (ABT-263), have shown promising antitumor efficacy in preclinical and early clinical stu

148 noparticles exhibited significantly improved antitumor efficacy in terms of tumor growth delay in bre

149 armacokinetic (PK) properties and remarkable antitumor efficacy in the BRCA1 mutant MX-1 breast cance

150 x-hA20 has a short serum half-life, it shows antitumor efficacy in tumor-bearing mice comparable with

151 duced serious diarrhea while maintaining the antitumor efficacy in tumor-bearing mice.

152 Anti-CD137 agonistic mAb has demonstrated antitumor efficacy in various tumor models and has now e

153 AUY922 exhibits antitumor efficacy in vitro and in vivo for EAC, suggest

154 lization, cytotoxicity, tumor targeting, and antitumor efficacy in vitro and in vivo over its nonsens

155 be synergistic with phototherapy to improve antitumor efficacy in vitro and in vivo, offering a new

156 th 17-AAG and doxorubicin exhibited superior antitumor efficacy in vivo in an ErbB2-driven xenograft

157 Most significantly, CMP-L-CA4 had better antitumor efficacy in vivo than its noncleavable (NC) an

158 mitter (125)I-DCIBzL yielded highly specific antitumor efficacy in vivo, suggesting promise for treat

159 nd interleukin (IL)-7/IL-15 was required for antitumor efficacy in vivo.

160 onality by means of restimulation ex vivo or antitumor efficacy in vivo.

161 oate-modified antisense oligonucleotides has antitumor efficacy in xenograft models of SCCHN.

162 agonist to the tumor site can contribute to antitumor efficacy, in the context of adoptive T-cell im

163 In terms of antitumor efficacy, iRGD coadministration significantly

164 tor I induction by IP6 plays any role in its antitumor efficacy is unknown.

165 tudy was to determine the antiangiogenic and antitumor efficacies of a vasculature-targeting fusion t

166 In severe combined immunodeficient mice, the antitumor efficacies of C1 and C2 were greater toward su

167 The antitumor efficacy of (211)At- 6: was evaluated in mice

168 ility of the probes to predict the potential antitumor efficacy of 2'-deoxy-2',2'-difluorocytidine (g

169 In this study, we investigated the antitumor efficacy of a CXCR4 antagonist expressed by on

170 cally, we analyzed how rapamycin affects the antitumor efficacy of a human papilloma virus E7 peptide

171 These results show the in vitro and in vivo antitumor efficacy of a prototype small molecule inhibit

172 Overall, our results argued that the antitumor efficacy of a virally based transgene therapeu

173 ignificantly increased the expansion and the antitumor efficacy of adoptively transferred pmel-1 CD8(

174 udies in murine models of ACT indicated that antitumor efficacy of adoptively transferred T cells is

175 hat targeting eEF-2 kinase may reinforce the antitumor efficacy of Akt inhibitors such as MK-2206.

176 for a combinatorial approach to enhance the antitumor efficacy of an OV, suggesting a strategy to im

177 y offers a general approach to retaining the antitumor efficacy of antibody-drug conjugates, while mi

178 ockdown of NAC1 expression can reinforce the antitumor efficacy of bevacizumab, an inhibitor of angio

179 We observed an outstanding antitumor efficacy of both (+/-)-ETP 2 and meso-ETP 2 in

180 t and depleting properties contribute to the antitumor efficacy of CD27-targeted immunotherapy, and m

181 7-DMAG-based "pulse" therapy may improve the antitumor efficacy of CD8(+) T effector cells reactive a

182 F-c-kit signaling blockade could improve the antitumor efficacy of chemotherapy of human NSCLC.

183 mice inhibits tumor growth and enhances the antitumor efficacy of cisplatin chemotherapy.

184 4, a key mediator of autophagy, enhanced the antitumor efficacy of cisplatin.

185 the chemical inhibitor brusatol enhanced the antitumor efficacy of cisplatin.

186 Finally, the antitumor efficacy of complex 1 was validated in the mur

187 ibe initial animal studies demonstrating the antitumor efficacy of compound 5 in vivo.

188 Importantly, we show that DFMO augments antitumor efficacy of conventional cytotoxics in vivo.

189 The synergistic antitumor efficacy of cotransferred activated B effector

190 of indoleamine 2,3-dioxygenase (IDO) on the antitumor efficacy of CTLA-4 blockade.

191 or function of CD8 TILs and thus improve the antitumor efficacy of current cancer vaccines.

192 Investigations in vivo showed equivalent antitumor efficacy of deoxynyboquinone to beta-lapachone

193 potential effects of sildenafil on improving antitumor efficacy of DOX in prostate cancer.

194 The antitumor efficacy of Doxil(R) is hindered by the poor r

195 her MyD88-dependent signaling may reduce the antitumor efficacy of EGFRIs in HNSCC.

196 6 pathway may be responsible for the reduced antitumor efficacy of erlotinib and other EGFRIs, and bl

197 e the potential of disulfiram to enhance the antitumor efficacy of external-beam gamma-irradiation an

198 This study evaluated the antitumor efficacy of farnesylthiosalicylic acid (FTA) l

199 In this study, we further showed the antitumor efficacy of Frzb in STS, a mesenchymal group o

200 likely, limit the protective and therapeutic antitumor efficacy of gamma9delta2T cells.

201 tumor environment may profoundly affect the antitumor efficacy of Hsp90-directed therapy.

202 Furthermore, bortezomib enhances the in vivo antitumor efficacy of IFN-gamma/TNF-alpha-inducing cytok

203 important obstacle to the evaluation of the antitumor efficacy of immunomodulator Abs in syngeneic m

204 ta pathway is a promising way to improve the antitumor efficacy of ionizing radiation and warrants cl

205 ating peptide improves tumor selectivity and antitumor efficacy of IP pro-apoptotic NWs.

206 eristics of tumors of origin to evaluate the antitumor efficacy of JQ1.

207 or, resulting in a marked improvement in the antitumor efficacy of lv immunization.

208 or immunotherapy and may explain the limited antitumor efficacy of lv immunization.

209 in vitro and in vivo, resulting in enhanced antitumor efficacy of lv immunization.

210 , while Fas signaling blockade preserved the antitumor efficacy of naive cells within mixed populatio

211 We demonstrate that the antitumor efficacy of nanoparticle is much superior to t

212 r in vitro as well as in vivo studies showed antitumor efficacy of NVP-LDE225 in combination with bor

213 UV irradiation in vitro and potentiated the antitumor efficacy of paclitaxel in a mouse xenograft mo

214 The antitumor efficacy of PF-2341066 was dose dependent and

215 The dual mechanism of action and robust antitumor efficacy of PF-5412 support its clinical devel

216 The antitumor efficacy of PR-171 delivered on 2 consecutive

217 G2 inhibitors would effectively increase the antitumor efficacy of purine nucleosides by blocking dru

218 This led to the hypothesis that the antitumor efficacy of rapamycin may be partially depende

219 We observed that the antitumor efficacy of rapamycin was reduced in the prese

220 c antigen receptors (CARs) have improved the antitumor efficacy of redirected T cells.

221 This study aims at characterizing the antitumor efficacy of sesamol and unveiling the importan

222 by chemotherapy or radiation can enhance the antitumor efficacy of several distinct, cell-based immun

223 These findings suggest in vivo antitumor efficacy of silibinin against CRC involving it

224 The antitumor efficacy of some taccalonolides, which stabili

225 Antitumor efficacy of subsequently infused 19-28z(+) eff

226 severely immunodeficient mice to assess the antitumor efficacy of systemic NBP treatments when combi

227 Antitumor efficacy of T cells depended on the presence o

228 t pathways of nuclear import that affect the antitumor efficacy of taxanes, suggesting a mechanistic

229 d by a therapeutic antibody can heighten the antitumor efficacy of the antibody.

230 rimary aim of this study was to evaluate the antitumor efficacy of the bromodomain inhibitor JQ1 in p

231 Itraconazole significantly enhanced the antitumor efficacy of the chemotherapeutic agent cisplat

232 oyed to investigate mechanisms of action and antitumor efficacy of the combination.

233 However, antitumor efficacy of the effector T cells generated fro

234 of CD4 or CD8 T cells completely eliminated antitumor efficacy of the lymphodepletion/anti-PD-L1 the

235 In the current study, we measured the antitumor efficacy of the S. typhimurium A1-R mutant, wh

236 The antitumor efficacy of the therapeutic 47-LDA-Fcgamma2a-D

237 We evaluated the antitumor efficacy of these viruses against neuroblastom

238 The antitumor efficacy of this anti-HER2-Rae-1beta fusion pr

239 M-CSF)-based immunotherapies can enhance the antitumor efficacy of this approach.

240 nd IL-2, and depletion of CD8(+) ablates the antitumor efficacy of this combination.

241 The antitumor efficacy of topotecan, (131)I-MIBG, and (131)I

242 ork provides direct evidence for the in vivo antitumor efficacy of TRAIL being proportional to system

243 Antitumor efficacy of TRAILPEG with tumor-homing sensiti

244 Despite intensive effort, the antitumor efficacy of tumor vaccines remains limited in

245 neutralizing anti-VSV antibodies negate the antitumor efficacy of VSV, a concern for repeat VSV admi

246 ggested by previous studies to have superior antitumor efficacy on various solid tumors.

247 M demonstrated dramatically enhanced in vivo antitumor efficacy over single treatment on nude mice be

248 ctor cells that display reduced survival and antitumor efficacy postinfusion.

249 ma was well tolerated and produced increased antitumor efficacy relative to the respective monotherap

250 in vivo are limited persistence and reduced antitumor efficacy, relative to CD8(+) T cells with a ce

251 Maximal antitumor efficacy required four components: a tumor-ant

252 Antitumor efficacy required stringent Treg depletion com

253 erstanding of the molecular determinants for antitumor efficacy resulting from RAF pathway inhibition

254 Affinity-tuned cells exhibited robust antitumor efficacy similar to high-affinity cells, but s

255 Targeted type I interferon elicits powerful antitumor efficacy, similar to wild-type IFN, but withou

256 In vivo antitumor efficacy studies in human prostate (PC-3) and

257 In vivo antitumor efficacy studies using mice inoculated with KB

258 However, antitumor efficacy study of beta-lap-dC3 micelles agains

259 -induced CD8(+) T-cell immunity and improved antitumor efficacy, suggesting manipulating beta-catenin

260 PF-5412 displayed robust and dose-dependent antitumor efficacy superior to that observed with IgG1/w

261 n was obtained by 20, which exhibited higher antitumor efficacy than 3 in PTEN-negative cancer cells

262 of B16F10 melanoma, Cim-F-alb showed higher antitumor efficacy than Abraxane at the same dose.

263 -VEGF-A antibodies did not result in greater antitumor efficacy than anti-VEGF-A monotherapy.

264 resulting in significantly improved clinical antitumor efficacies that have transformed the clinical

265 rgeted therapies, such as less-than-expected antitumor efficacy that may arise from compensatory incr

266 th acceptable toxicity and promising durable antitumor efficacy that warrant further testing in a ran

267 gamma responses can lead to successful early antitumor efficacy, they may also impair the development

268 ough blockade of both CD73 and A2AR enhances antitumor efficacy through distinct mechanisms.

269 We conclude that rQT3 enhanced antitumor efficacy through multiple mechanisms, includin

270 tial immunization with DNA and Ad5 maximized antitumor efficacy through TCR avidity enhancement, it p

271 ichia coli by the disk diffusion method, and antitumor efficacy toward the HeLa cell-derived tumor sp

272 ics and in vivo pharmacokinetics that define antitumor efficacy under intermittent dosing conditions.

273 atory target and to address the mechanism of antitumor efficacy using different IgG isotypes of 1F5 i

274 a foreign gene can be selected for enhanced antitumor efficacy via in vivo serial passage within fla

275 In the current study, superior antitumor efficacy was achieved by further increasing th

276 Antitumor efficacy was demonstrated for (E1)-3s coadmini

277 Nonetheless, significant antitumor efficacy was documented after anti-DR5 deliver

278 use PDA xenografts (+MUC1 or MUC1 null), and antitumor efficacy was further improved when the virus w

279 This increased antitumor efficacy was observed in several experimental

280 A stronger antitumor efficacy was observed with silybin-phytosome p

281 Antitumor efficacy was quantified in vivo using 4T1 brea

282 Potent antitumor efficacy was shown using the mouse mammary tum

283 Antitumor efficacy was significantly abrogated on blocka

284 In vivo antitumor efficacy was tested in nude mice bearing PSMA+

285 o determine the mechanisms of chNKG2D T cell antitumor efficacy, we analyzed how chNKG2D T cells alte

286 e binding affinity to p185(her2/neu) and the antitumor efficacy, we have engineered a fusion protein

287 ics (PKs), pharmacodynamics, and preliminary antitumor efficacy were assessed in a phase I study of M

288 Antiangiogenesis and antitumor efficacy were associated with disrupted co-loc

289 decreased human vessel density and improved antitumor efficacy when combined with bevacizumab (anti-

290 r-bearing mice showed significantly improved antitumor efficacy when combined with either 5-aziridiny

291 Compound 50 also showed excellent in vivo antitumor efficacy when dosed orally in an A2780 ovarian

292 Compound 25b exhibited significant in vivo antitumor efficacy when dosed orally in an ALK-positive

293 rime or prime-boost regimens correlated with antitumor efficacy, whereas T cell number and cytokine p

294 erent valencies did not significantly affect antitumor efficacy, whereas the presence of an Fc domain

295 ors targeting EGFR have demonstrated limited antitumor efficacy, which may be explained, in part, by

296 les in the clinic, MYD1-72 achieved superior antitumor efficacy while displaying no toxicity.

297 murine monocytes and results in an enhanced antitumor efficacy with dl309 in vivo.

298 covered compound 15d, which demonstrated the antitumor efficacy with oral bioavailability.

299 f ATR have been reported showing significant antitumor efficacy, with most advanced ones entering cli

300 idity enhancement eliminated GUCY2C-specific antitumor efficacy, without affecting responding T cell